7

From 2011.igem.org

(Difference between revisions)
 
(5 intermediate revisions not shown)
Line 1: Line 1:
<html>
<html>
-
<b>Rebekka Bauer</b><br><br>
+
 
-
novel in vivo mutagenesis mechanism:<br>
+
 
-
-construct target genomic DNA with really strong promoter with retrovirus recognition sequence (R U5 PBS etc to ensure that only this is reverse transcribed)<br>
+
 
-
-transcribe into RNA using a crap RNA pol that introduces mutations<br>
+
<b>Talk from LSE</b><br>
-
-reverse transcribe into DNA using an overexpressed reverse transcriptase (overexpressed to ensure that this happens before DNA is degraded). The RT should be coupled to an inducible promoter to ensure that mutagenesis only takes place in bursts.<br>
+
Things to consider in human practices:<br>
-
-insert into genome via homologous recombination using an equivalent of infusion enzyme (maybe RecA?)<br>
+
Safety, Security, IP-intellectual property, ethical, biohacking, global fairness<br>
-
</html>
+
For Anti-venom project<br>
 +
Safety : handling toxin in the lab, storage and transportation of toxins<br>
 +
Security : produce specificity problem, antivenom target for particular person<br>
 +
Patent : only the process obtaining product(antibody) but not the product itself, patent cost a lot of money <br>
 +
LEGO exercise:<br>
 +
- different ways to describe the construction process<br>
 +
- engineering language and user-friendly language<br><br>
 +
 
 +
Contacts of people from RCA and LSE <br><br>
 +
RCA<br>
 +
- Pei-Ying Lin : peiying.lin@networkrca.ac.uk<br>
 +
- Koby : yaacov.barhad@network.rca.ac.uk<br>
 +
- CJ : charlotte@artforeating.com<br><br>
 +
LSE<br>
 +
- Alex Hamilton : r.a.hamilton@LSE.ac.uk <br>
 +
- Claire MArris : c.marris@lse.ac.uk <br>
 +
- Stephan Guttinges : s.m.guettinges@lse.ac.uk <br><br>
 +
 
 +
 
 +
(Text by Ming, Nina, Si, Yuanwei and Nick)

Latest revision as of 11:57, 12 July 2011

Talk from LSE
Things to consider in human practices:
Safety, Security, IP-intellectual property, ethical, biohacking, global fairness
For Anti-venom project
Safety : handling toxin in the lab, storage and transportation of toxins
Security : produce specificity problem, antivenom target for particular person
Patent : only the process obtaining product(antibody) but not the product itself, patent cost a lot of money
LEGO exercise:
- different ways to describe the construction process
- engineering language and user-friendly language

Contacts of people from RCA and LSE

RCA
- Pei-Ying Lin : peiying.lin@networkrca.ac.uk
- Koby : yaacov.barhad@network.rca.ac.uk
- CJ : charlotte@artforeating.com

LSE
- Alex Hamilton : r.a.hamilton@LSE.ac.uk
- Claire MArris : c.marris@lse.ac.uk
- Stephan Guttinges : s.m.guettinges@lse.ac.uk

(Text by Ming, Nina, Si, Yuanwei and Nick)

Retrieved from "http://2011.igem.org/7"